Get started
BIOMARIN PHARMACEUTICAL INCBIOMARIN PHARMACEUTICAL INCBIOMARIN PHARMACEUTICAL INC

BIOMARIN PHARMACEUTICAL INC

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Forecast Seasonals Bonds

BMRN chart


Full chart

BMRN upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪250.27 B‬ MXN
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
40.31
Basic EPS (TTM)
33.46 MXN
Net income (FY)
‪2.85 B‬ MXN
Revenue (FY)
‪41.09 B‬ MXN
Shares float
‪188.20 M‬
Beta (1Y)
0.39

Employees


Employees (FY)
‪3.4 K‬
Change (1Y)
+319 +10.35%
Revenue / Employee (1Y)
‪711.38 K‬ MXN
Net income / Employee (1Y)
‪49.29 K‬ MXN

About BioMarin Pharmaceutical Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Alexander Hardy
Website
biomarin.com
Headquarters
San Rafael
Founded
1997
FIGI
BBG00PG3KTH6
BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997, and is headquartered in San Rafael, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

BMRN news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

BMRN highest yielding bonds


BMRN5187965
BioMarin Pharmaceutical Inc. 1.25% 15-MAY-2027
Yield to maturity
4.87%
Maturity date
May 15, 2027

Explore more bonds 

Sparks


Curated watchlists where BMRN is featured.

See all sparks 

Frequently Asked Questions


The current price of BMRN is 1,400.00 MXN — it has increased by 2.34% in the past 24 hours. Watch BIOMARIN PHARMACEUTICAL INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BIVA exchange BIOMARIN PHARMACEUTICAL INC stocks are traded under the ticker BMRN.
BMRN stock has risen by 4.14% compared to the previous week, the month change is a 3.30% rise, over the last year BIOMARIN PHARMACEUTICAL INC has showed a −10.54% decrease.
We've gathered analysts' opinions on BIOMARIN PHARMACEUTICAL INC future price: according to them, BMRN price has a max estimate of 2,568.46 MXN and a min estimate of 1,314.57 MXN. Watch BMRN chart and read a more detailed BIOMARIN PHARMACEUTICAL INC stock forecast: see what analysts think of BIOMARIN PHARMACEUTICAL INC and suggest that you do with its stocks.
BMRN stock is 4.14% volatile and has beta coefficient of 0.39. Track BIOMARIN PHARMACEUTICAL INC stock price on the chart and check out the list of the most volatile stocks — is BIOMARIN PHARMACEUTICAL INC there?
Today BIOMARIN PHARMACEUTICAL INC has the market capitalization of ‪250.27 B‬, it has decreased by −3.43% over the last week.
Yes, you can track BIOMARIN PHARMACEUTICAL INC financials in yearly and quarterly reports right on TradingView.
BIOMARIN PHARMACEUTICAL INC is going to release the next earnings report on Feb 20, 2025. Keep track of upcoming events with our Earnings Calendar.
BMRN earnings for the last quarter are 10.84 MXN per share, whereas the estimation was 10.46 MXN resulting in a 3.59% surprise. The estimated earnings for the next quarter are 11.25 MXN per share. See more details about BIOMARIN PHARMACEUTICAL INC earnings.
BIOMARIN PHARMACEUTICAL INC revenue for the last quarter amounts to ‪14.69 B‬ MXN, despite the estimated figure of ‪13.86 B‬ MXN. In the next quarter, revenue is expected to reach ‪14.58 B‬ MXN.
BMRN net income for the last quarter is ‪2.09 B‬ MXN, while the quarter before that showed ‪1.97 B‬ MXN of net income which accounts for 6.33% change. Track more BIOMARIN PHARMACEUTICAL INC financial stats to get the full picture.
No, BMRN doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 24, 2024, the company has ‪3.40 K‬ employees. See our rating of the largest employees — is BIOMARIN PHARMACEUTICAL INC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. BIOMARIN PHARMACEUTICAL INC EBITDA is ‪9.66 B‬ MXN, and current EBITDA margin is 12.35%. See more stats in BIOMARIN PHARMACEUTICAL INC financial statements.
Like other stocks, BMRN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade BIOMARIN PHARMACEUTICAL INC stock right from TradingView charts — choose your broker and connect to your account.